Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ATM | Q13315 | 1/20 | 0.32 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.32 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.32 |
| ▸ | CHRM2 | P08172 | 3/20 | 0.31 |
| ▸ | CHRM4 | P08173 | 3/20 | 0.31 |
| ▸ | CHRM5 | P08912 | 3/20 | 0.31 |
| ▸ | CHRM1 | P11229 | 3/20 | 0.31 |
| ▸ | CHRM3 | P20309 | 3/20 | 0.31 |
| ▸ | CHRNB2 | P17787 | 1/20 | 0.30 |
| ▸ | CHRNB4 | P30926 | 1/20 | 0.30 |
| ▸ | CHRNA3 | P32297 | 1/20 | 0.30 |
| ▸ | CHRNA7 | P36544 | 1/20 | 0.30 |
| ▸ | CHRNA4 | P43681 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20161407 | 1.00 | ATM (0.32) | ATML3MBTL1SMN1; SMN2CHRM2CHRM4 | |
| SCHEMBL15177476 | 1.00 | ATM (0.32) | ATML3MBTL1SMN1; SMN2CHRM2CHRM4 | |
| SCHEMBL23468934 | 0.90 | KDM4E (0.35) | ATML3MBTL1SMN1; SMN2 | |
| SCHEMBL2741016 | 0.83 | — | — | |
| SCHEMBL81182 | 0.83 | — | — | |
| SCHEMBL10196624 | 0.83 | — | — | |
| SCHEMBL19144 | 0.81 | NCF1 (0.33) | CHRM1 | |
| SCHEMBL12367162 | 0.81 | NCF1 (0.33) | CHRM1 | |
| SCHEMBL19334279 | 0.75 | — | — | |
| SCHEMBL8242173 | 0.75 | KDM4E (0.32) | ATML3MBTL1SMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2023196278-A1 | ITK INHIBITORS FOR INCREASING TH1 CELL ACTIVITY | CORVUS PHARMACEUTICALS, INC. (US) | 2023-10-12 | — | — | WO | disclosed |
| EP-3534899-B1 | COMPOUNDS AND METHODS FOR MODULATING INTERLEUKIN-2-INDUCIBLE T-CELL KINASE | CORVUS PHARMACEUTICALS INC (US) | 2022-06-01 | — | — | EP | disclosed |
| US-11008314-B2 | Compounds and methods for modulating interleukin-2-inducible t-cell kinase | CORVUS PHARMACEUTICALS, INC. (US) | 2021-05-18 | — | — | US | disclosed |
| WO-2018089261-A2 | COMPOUNDS AND METHODS FOR MODULATING INTERLEUKIN-2-INDUCIBLE T-CELL KINASE | CORVUS PHARMACEUTICALS, INC. (US) | 2018-05-17 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11008314-B2 | Compounds and methods for modulating interleukin-2-inducible t-cell kinase | IL2, NFATC1, IL2RA | ATM 909/4885L3MBTL1 1737/4885SMN1; SMN2 4518/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.